心臓移植拒絶反応:治療薬パイプラインレビュー

【英語タイトル】Heart Transplant Rejection - Pipeline Review, H1 2018

Global Markets Directが出版した調査資料(GMDHC10549IDB)・商品コード:GMDHC10549IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2018年6月12日
・ページ数:32
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site PriceUSD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprise PriceUSD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Heart Transplant Rejection – Pipeline Review, H1 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Heart Transplant Rejection – Pipeline Review, H1 2018, provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape.

Table of ContentsTable of Contents 2List of Tables

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Heart Transplant Rejection – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Heart Transplant Rejection (Immunology)
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heart Transplant Rejection (Immunology) pipeline guide
The guide covers therapeutics under Development by Companies /Universities /Institutes,
Heart Transplant Rejection – Pipeline Review, H1 2018 Reference Code: GMDHC10549IDBPublication Date: June 2018­

Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is
Heart Transplant Rejection – Pipeline Review, H1 2018 Reference Code: GMDHC10549IDBPublication Date: June 2018­ Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heart Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heart Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heart Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heart Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heart Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heart Transplant Rejection – Overview
Heart Transplant Rejection – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Heart Transplant Rejection – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heart Transplant Rejection – Companies Involved in Therapeutics Development
Astellas Pharma Inc
Heat Biologics Inc
Noxxon Pharma AG
TxCell SA
Heart Transplant Rejection – Drug Profiles
2C-10 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-2521780 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-2553627 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emapticap pegol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENTX-MS – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTX-15 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK3 for Heart Transplantation – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heart Transplant Rejection – Dormant Projects
Heart Transplant Rejection – Product Development Milestones
Featured News & Press Releases
Sep 27, 2017: Pelican Therapeutics Announces Manufacturing Agreement with KBI Biopharma to Advance PTX-15 Fusion Protein
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Heart Transplant Rejection, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Heart Transplant Rejection - Pipeline by Astellas Pharma Inc, H1 2018
Heart Transplant Rejection - Pipeline by Heat Biologics Inc, H1 2018
Heart Transplant Rejection - Pipeline by Noxxon Pharma AG, H1 2018
Heart Transplant Rejection - Pipeline by TxCell SA, H1 2018
Heart Transplant Rejection - Dormant Projects, H1 2018

List of Figures
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

★調査レポート[心臓移植拒絶反応:治療薬パイプラインレビュー] (コード:GMDHC10549IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[心臓移植拒絶反応:治療薬パイプラインレビュー]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆